Peter Salgo, MD, Columbia University Irving Medical Center

Thought leaders in diabetes provide closing remarks about the importance of continuous awareness of glycemic control in patients as well as the need for effective communication between patients and providers. 

A panel of experts in the treatment of diabetes discusses the importance of self-management of blood glucose levels and emphasizes the need for multidisciplinary care teams and referrals for optimal disease management.

Key opinion leaders in endocrinology provide an overview of factors to consider when selecting or switching intranasal and injectable glucagon including ease of administration and patient preference.

Thought leaders in diabetes discuss challenges of insurance coverage for new formulations of glucagon and comment on the potential for long-term cost savings due to decreased overall healthcare system utilization.

Experts in endocrinology build a discussion on new intranasal and injectable formulations of glucagon and discuss their benefits compared to glucagon kits that require reconstitution.

A panel of thought leaders in the management of diabetes reviews the mainstays of treatment for hypoglycemic episodes and builds a discussion on effective non-pharmacologic strategies for raising blood glucose levels.

Panelists consider the importance of long-term approaches to monitoring hypoglycemic episodes and discuss the role of education and awareness, patient questionnaires, and effective communication with physicians.

Key opinion leaders in diabetes comment on various blood glucose tests to assess hypoglycemia and prevent future episodes.

A multidisciplinary panel of experts shares insights into identifying symptoms of hypoglycemia and highlights the importance of stratifying level 1, 2, and 3 blood glucose levels when making the differential diagnosis in diabetes.

Expert panelists provide an overview of health complications associated with mild and severe hypoglycemic episodes and emphasize the importance of patient awareness and early recognition to improve quality of life and health-related outcomes.

Key thought leaders in endocrinology review different signs and symptoms of hypoglycemia across vulnerable patient populations and discuss factors that may impact the pharmacologic management of blood glucose levels.

A panel of experts in diabetes builds a discussion on hypoglycemia and shares key insights into its impact on community health by considering overall challenges of glucose management.

A panel of experts in schizophrenic psychiatric care share their thoughts on the practice, patients, and treatment based on their years of experience.

Joe Avelino, RN, BSN, MHSA, CPHQ, and Rahn Bailey, MD, DFAPA, explain protocols a practice can follow when managing a patient with schizophrenia who is frequently hospitalized or has other medical conditions.

Rahn Bailey, MD, DFAPA, explains why long-acting injectables are under prescribed in patients with schizophrenia and why doctors choose not to use them as a first-line treatment.

The multidisciplinary panel of experts share final thoughts on strategies to normalize naloxone and decrease barriers to its obtainment and utilization.

Joe Avelino, RN, BSN, MHSA, CPHQ, describes the patient care protocols upon discharge from the inpatient setting to the outpatient setting to assure that patients will continue their care.

Experts in the field of psychiatry discuss the differences between other specialties and psychiatry as well as the inconsistency within psychiatry itself.

Charles Argoff, MD, leads a discussion on the use of pain contracts versus pain agreements between clinicians and patients to bring about desired outcomes.

Experts discuss the need for and impact of peer-to-peer discussion initiatives, as well as the impact telemedicine utilization has had on the opioid crisis.

Henry Nasrallah, MD, compares the European Guidelines and United States Guidelines; the panel discusses guidelines currently in place for psychiatric patients.

Joe Avelino, RN, BSN, MHSA, CPHQ, defines a hospital versus an institution; and Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the lack of guideline-supported protocols for patients

Experts share insights on how they have utilized Prescription Monitoring Programs to combat the opioid crisis and improve the safety of prescribed opioids.

Experts share approaches to normalize conversations about naloxone with patients, as well as share important considerations for maximizing naloxone education.

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, review how early long-acting injectables should be started in patients with schizophrenia.

Henry Nasrallah, MD, and Rahn Bailey, MD, DFAPA, discuss how to switch a patient from oral to a long-acting injectable antipsychotic from their own experience.

Multidisciplinary panel of clinicians discuss whether recommendations made by national, state, and local agencies infringes upon clinical practice autonomy. 

Jeffrey Bratberg, PharmD, FAPhA, and Joshua Lynch, DO, EMT-P, FAAEM, FACEP, discuss highlights from the December 2020 CDC Health Alert and application.

Joe Avelino, RN, BSN, MHSA, CPHQ, reviews the benefits of using long-acting injectables (LAIs) and Henry Nasrallah, MD, reviews his techniques for getting patients to accept LAIs and continue with them. 

Henry Nasrallah, MD, discusses patient factors that lead to long-acting injectable treatment in patients with schizophrenia.